![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PPT2 |
Gene summary for PPT2 |
![]() |
Gene information | Species | Human | Gene symbol | PPT2 | Gene ID | 9374 |
Gene name | palmitoyl-protein thioesterase 2 | |
Gene Alias | C6orf8 | |
Cytomap | 6p21.32 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A1U9X8D2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9374 | PPT2 | HCC1_Meng | Human | Liver | HCC | 2.48e-42 | 1.33e-01 | 0.0246 |
9374 | PPT2 | HCC1 | Human | Liver | HCC | 7.38e-03 | 2.54e+00 | 0.5336 |
9374 | PPT2 | Pt13.b | Human | Liver | HCC | 8.69e-06 | 7.54e-02 | 0.0251 |
9374 | PPT2 | S014 | Human | Liver | HCC | 3.27e-12 | 3.44e-01 | 0.2254 |
9374 | PPT2 | S015 | Human | Liver | HCC | 2.65e-20 | 6.53e-01 | 0.2375 |
9374 | PPT2 | S016 | Human | Liver | HCC | 1.06e-18 | 5.04e-01 | 0.2243 |
9374 | PPT2 | S028 | Human | Liver | HCC | 1.31e-03 | 1.16e-01 | 0.2503 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000911722 | Liver | HCC | nucleotide metabolic process | 300/7958 | 489/18723 | 1.61e-17 | 1.71e-15 | 300 |
GO:000675322 | Liver | HCC | nucleoside phosphate metabolic process | 304/7958 | 497/18723 | 1.78e-17 | 1.85e-15 | 304 |
GO:001969322 | Liver | HCC | ribose phosphate metabolic process | 248/7958 | 396/18723 | 3.15e-16 | 2.70e-14 | 248 |
GO:000925922 | Liver | HCC | ribonucleotide metabolic process | 240/7958 | 385/18723 | 2.07e-15 | 1.51e-13 | 240 |
GO:000679021 | Liver | HCC | sulfur compound metabolic process | 212/7958 | 339/18723 | 5.60e-14 | 3.39e-12 | 212 |
GO:000915022 | Liver | HCC | purine ribonucleotide metabolic process | 226/7958 | 368/18723 | 1.36e-13 | 7.69e-12 | 226 |
GO:007252122 | Liver | HCC | purine-containing compound metabolic process | 250/7958 | 416/18723 | 2.26e-13 | 1.24e-11 | 250 |
GO:000616322 | Liver | HCC | purine nucleotide metabolic process | 236/7958 | 396/18723 | 3.59e-12 | 1.62e-10 | 236 |
GO:00338652 | Liver | HCC | nucleoside bisphosphate metabolic process | 88/7958 | 128/18723 | 1.63e-09 | 4.78e-08 | 88 |
GO:00338752 | Liver | HCC | ribonucleoside bisphosphate metabolic process | 88/7958 | 128/18723 | 1.63e-09 | 4.78e-08 | 88 |
GO:00340322 | Liver | HCC | purine nucleoside bisphosphate metabolic process | 88/7958 | 128/18723 | 1.63e-09 | 4.78e-08 | 88 |
GO:00066372 | Liver | HCC | acyl-CoA metabolic process | 67/7958 | 96/18723 | 5.62e-08 | 1.19e-06 | 67 |
GO:00353832 | Liver | HCC | thioester metabolic process | 67/7958 | 96/18723 | 5.62e-08 | 1.19e-06 | 67 |
GO:000916512 | Liver | HCC | nucleotide biosynthetic process | 150/7958 | 254/18723 | 6.79e-08 | 1.40e-06 | 150 |
GO:190129312 | Liver | HCC | nucleoside phosphate biosynthetic process | 151/7958 | 256/18723 | 6.84e-08 | 1.41e-06 | 151 |
GO:00442722 | Liver | HCC | sulfur compound biosynthetic process | 95/7958 | 148/18723 | 7.89e-08 | 1.58e-06 | 95 |
GO:004639012 | Liver | HCC | ribose phosphate biosynthetic process | 116/7958 | 190/18723 | 1.79e-07 | 3.29e-06 | 116 |
GO:000926012 | Liver | HCC | ribonucleotide biosynthetic process | 111/7958 | 182/18723 | 3.53e-07 | 6.03e-06 | 111 |
GO:000915212 | Liver | HCC | purine ribonucleotide biosynthetic process | 101/7958 | 169/18723 | 4.30e-06 | 5.50e-05 | 101 |
GO:007252212 | Liver | HCC | purine-containing compound biosynthetic process | 114/7958 | 200/18723 | 2.36e-05 | 2.49e-04 | 114 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa041422 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
hsa000622 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
hsa041423 | Liver | HCC | Lysosome | 100/4020 | 132/8465 | 2.32e-11 | 4.31e-10 | 2.40e-10 | 100 |
hsa012125 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
hsa0006211 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPT2 | SNV | Missense_Mutation | c.319G>T | p.Ala107Ser | p.A107S | Q9UMR5 | protein_coding | tolerated(0.38) | benign(0.258) | TCGA-49-AARQ-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PPT2 | SNV | Missense_Mutation | novel | c.446N>G | p.Tyr149Cys | p.Y149C | Q9UMR5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-63-A5MU-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | PD |
PPT2 | SNV | Missense_Mutation | c.312G>A | p.Met104Ile | p.M104I | Q9UMR5 | protein_coding | tolerated(0.17) | benign(0.283) | TCGA-70-6722-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD | |
PPT2 | SNV | Missense_Mutation | novel | c.122N>T | p.Ser41Phe | p.S41F | Q9UMR5 | protein_coding | tolerated(0.07) | benign(0.003) | TCGA-90-A4ED-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PPT2 | SNV | Missense_Mutation | rs751977544 | c.350C>T | p.Ser117Leu | p.S117L | Q9UMR5 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-KU-A6H7-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PPT2 | insertion | Frame_Shift_Ins | rs756707985 | c.832dupG | p.Ala278GlyfsTer23 | p.A278Gfs*23 | Q9UMR5 | protein_coding | TCGA-CV-A6K1-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
PPT2 | SNV | Missense_Mutation | novel | c.453C>A | p.Asp151Glu | p.D151E | Q9UMR5 | protein_coding | tolerated(0.06) | probably_damaging(0.976) | TCGA-ZG-A9LN-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Hormone Therapy | trenantone | SD |
PPT2 | SNV | Missense_Mutation | c.425N>T | p.Ser142Phe | p.S142F | Q9UMR5 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-BR-4187-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
PPT2 | SNV | Missense_Mutation | c.521N>A | p.Pro174His | p.P174H | Q9UMR5 | protein_coding | tolerated(0.17) | benign(0.007) | TCGA-BR-4201-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | SD | |
PPT2 | SNV | Missense_Mutation | c.440G>A | p.Gly147Glu | p.G147E | Q9UMR5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-HU-A4GX-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |